Surrozen Inc., abbreviated as SRZN, is a biotechnology company renowned for its cutting-edge research and innovative solutions in the field of regenerative medicine. The company is based in South San Francisco, California, and it was publicly listed on NASDAQ in February 2021.
Surrozen is dedicated to harnessing the extraordinary power of Wnt ligands, a group of signaling molecules that play crucial roles in tissue health and repair. The company holds a high scientific regard for these Wnt ligands due to their fundamental role in the functioning of stem cells and their potential for tissue regeneration and maintenance.
A key facet of Surrozen’s operations is its proprietary technology platforms - SWEETS (Surrozen Wnt Enzyme Enhanced Therapeutic System) and SWAP (Surrozen Wnt Allosteric Platform). These platforms have been instrumental in the development of novel therapeutic candidates which have the potential to significantly advance the field of regenerative medicine.
The SWEETS platform enables the production of engineered Wnt proteins which stimulate tissue repair through the direct activation of Wnt signaling pathways. On the other hand, the SWAP platform is designed to generate small molecule Wnt pathway agonists that can mimic the regenerative effects of Wnts.
Surrozen’s clinical pipeline encompasses programs for various severe diseases such as liver disease, lung disease, and neurodegenerative disorders, amongst others. In the pursuit of making a significant clinical impact, SRZN is actively working on expanding its therapeutic portfolio to cater to a wider range of diseases requiring tissue repair and regeneration.
In terms of corporate governance, Surrozen is guided by a team of field experts with extensive experience in biopharmaceuticals, clinical development, and medical research. The wide-ranging expertise of its leaders, combined with the dedication of its workforce, drive the company towards fulfilling its mission of developing transformative therapies.
The company's commitment to groundbreaking medical research combined with a forward-thinking approach makes Surrozen a leader in the field of regenerative medicine. Its remarkable strides in resolving challenging health issues and unmet medical needs demonstrate not only its innovative prowess but also its commitment to improving human health. With its pioneering research efforts, Surrozen continues to push the boundaries in the realm of therapeutic development.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article analyzes Surrozen Inc. (NASDAQ: SRZN), identifying a positive near-term sentiment that may counter a mid-term weak bias within a long-term strong context. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also provides multi-timeframe signal strengths and support/resistance levels for the stock.
Guggenheim Securities has named Surrozen, Inc. as its top biotechnology stock pick, initiating coverage with a Buy rating and a $42.00 price target. The firm believes Surrozen is significantly undervalued and highlights its lead drug candidate, SZN-8141, which combines Wnt agonism with anti-VEGF therapy for retinal vascular diseases. Key catalysts include the initiation of the DUET study by year-end 2026 and initial data expected in the second half of 2027.
Surrozen Inc. (NASDAQ: SRZN) is showing weak near and mid-term sentiment despite a positive long-term outlook. An exceptional short setup is identified with a high risk-reward ratio, targeting significant downside. The article details institutional trading strategies including position trading, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis.
Surrozen, Inc. has received FDA clearance for its investigational new drug (IND) application for SZN-8141, a bifunctional antibody for treating diabetic macular edema (DME) and wet age-related macular degeneration (AMD). This clearance allows Surrozen to begin human clinical evaluations with the phase 1b/2a DUET study, expected to start patient dosing in Q4 2026. The company is also set to acquire an estimated $95.1 million in funding to support its clinical development plans.
Surrozen (NASDAQ:SRZN) experienced an 11.3% decline on October 13, 2026, trading on light volume, with no apparent catalyst or company news. This drop partially retraces a 11.2% gain from October 8, which also occurred without a clear reason. The company develops antibody drugs for eye and liver diseases, and its value is primarily driven by clinical trial data and financing, making it susceptible to significant price movements based on such binary events.